retatrutide clinical trials phase 3 (“reta”) is an experimental weight-loss drug currently in trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works What GLP‑3 Really Is: Retatrutide
Description
Intra-articular injection of C57Bl/6 mice with an adenovirus vector overexpressing active TGF- [86] or repeated in-articular injections of recombinant TGF- induced hyperplasia of synovium with increases in inflammatory immune cells, including macrophages [87]
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist, not a GLP-1 receptor agonist
When growth hormone levels rise, visceral fat breaks down preferentially
Even if that's true at high enough oral doses (the evidence is mixed), it's a fundamentally different mechanism from a prescription GLP-1 medicine
To obtain Professional Liability Insurance, carriers will often want to know about the experience of the medspas medical director, the qualifications of providers, and the scope of services being offered
The Summary of Product Characteristics (SmPC) for these medications does not currently list blood clots as a recognised adverse effect
